A Phase III Study to Evaluate the Efficacy and Safety of GSK1358820 (Botulinum Toxin Type A) in Patients With Overactive Bladder
Latest Information Update: 30 Aug 2023
At a glance
- Drugs Botulinum-Toxin-A (Primary)
- Indications Overactive bladder; Urinary incontinence
- Focus Registrational; Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 08 Jan 2019 Status changed from active, no longer recruiting to completed.
- 01 Dec 2017 Status changed from recruiting to active, no longer recruiting.
- 25 Aug 2016 Status changed from not yet recruiting to recruiting.